Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596172 | 0.86 | POLB (0.62) | POLBLPAR1ALDH1A1MAPTTSHR | |
| SCHEMBL6348301 | 0.85 | POLB (0.61) | POLBLPAR1ALDH1A1MAPTTSHR | |
| SCHEMBL536527 | 0.83 | POLB (0.59) | POLBLPAR1ALDH1A1MAPTTSHR | |
| SCHEMBL31040567 | 0.82 | POLB (0.77) | POLBLPAR1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4554983 | 0.82 | POLB (0.77) | POLBLPAR1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13255726 | 0.82 | POLB (0.62) | POLBLPAR1ALDH1A1MAPTTSHR | |
| Hydrochloric Acid SCHEMBL8974944 | 0.82 | ALDH1A1 (0.60) | POLBLPAR1ALDH1A1MAPTTSHR | |
| SCHEMBL8930775 | 0.82 | POLB (0.58) | POLBLPAR1ALDH1A1MAPTTSHR | |
| Benzene SCHEMBL7277187 | 0.81 | TSHR (0.58) | POLBLPAR1ALDH1A1MAPTTSHR | |
| SCHEMBL12125175 | 0.81 | KMT2A (0.76) | POLBLPAR1ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974790-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | POLB 430/4885LPAR1 3579/4885ALDH1A1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.